EPGNF Projected Dividend Yield
EPIGENOMICS AG BERLIN ( OTCBB : EPGNF )Epigenomics is a holding company. Through its Epigenomics Inc. subsidiary, Co. is engaged as a molecular diagnostics company focusing on developing and commercializing of in vitro diagnostic (IVD) tests for the screening and diagnosis of cancer. Co.'s products are based on a proprietary technology platform, which utilizes a biological phenomenon called DNA methylation as a source for the discovery of disease-specific biomarkers. Co. develops and commercializes cancer diagnostic tests in colorectal cancer (CRC) and in lung cancer. Co.'s key product is Epi proColon®, a blood-based test for the early detection of CRC which utilizes its proprietary DNA methylation biomarker, Septin9. 20 YEAR PERFORMANCE RESULTS |
EPGNF Dividend History Detail EPGNF Dividend News EPGNF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |